[an error occurred while processing this directive] | [an error occurred while processing this directive]
Comparison of target dosimetry and treatment outcome in patients with stage Ⅲ non-small cell lung cancer treated with three-dimensional conformal radiotherapy and intensity-modulated radiotherapy
Wang Yuxiang, Tian Xiuming, Qiu Rong, Wang Lili, Zhu Shuchai
Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
Abstract Objective To compare the target dosimetric distribution and clinical outcome in patients with stage Ⅲ non-small cell lung cancer (NSCLC) treated with three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). Methods The clinical data of 419 patients with stage Ⅲ NSCLC treated with either 3DCRT or IMRT were retrospectively analyzed. Among them, there were 338 male and 81 female patients, and the median age was 63 years (range:32－84 years). There were 340 patients treated with 3DCRT and 79 with IMRT, and the median prescribed dose was 60 Gy (range:50－76 Gy). One hundred and forty patients were treated with radiotherapy alone and 279 were treated with chemoradiotherapy. The target dosimetric distribution was evaluated with dose-volume histogram (DVH) parameters. The overall survival (OS) rate was calculated using the Kaplan-Meier method and analyzed by the log-rank test. Results When comparing the clinical data, the patients treated with 3DCRT were in older ages, and had advanced N and clinical stages (P=0.01, 0.00, and 0.00, respectively). When comparing the target DVH parameters, the patients treated with IMRT had larger planning target volume (PTV)(P=0.01), significantly lower clinical target volume (CTV) Dmean, CTV D90, PTV Dmean, and PTV V65-V60(P=0.05－0.01), significantly higher V5-V20 in both lungs, higher esophagus Dmean, longer esophagus in the radiation field, higher linear energy transfer between 45 and 55 keV/μm (LET45-LET55), and higher spinal cord Dmean(P=0.03－0.00). The follow-up rate was 97.4%. After radiotherapy, the 1-, 3-, and 5-year OS rates were 65.5%, 26.1%, and 18.5%, respectively, and the median survival time was 20 months. There were no significant differences in OS rate and the incidence of acute radiation pneumonitis and radiation esophagitis between patients treated with IMRT and 3DCRT (P=0.06,0.73,0.13). Stratified analysis showed that, when comparing the patients treated with IMRT with those treated with 3DCRT, the survival rate was only lower in male patients, patients in stage T3-T4 or N0-N2, and those without chemotherapy (P=0.04,0.04,0.02,0.00). Conclusions The treatment outcomes of patients with stage Ⅲ NSCLC undergoing IMRT and 3DCRT are comparable. IMRT shows a potential dosimetric advantage, but the result needs further investigation.
Wang Yuxiang,Tian Xiuming,Qiu Rong et al. Comparison of target dosimetry and treatment outcome in patients with stage Ⅲ non-small cell lung cancer treated with three-dimensional conformal radiotherapy and intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(2): 126-130.
Wang Yuxiang,Tian Xiuming,Qiu Rong et al. Comparison of target dosimetry and treatment outcome in patients with stage Ⅲ non-small cell lung cancer treated with three-dimensional conformal radiotherapy and intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(2): 126-130.
[1]阿依古丽·卡力,张瑾熔,王巨武,等.肺癌CT及X线模拟定位放疗计划的剂量学比较研究[J].中华放射肿瘤学杂志,2007,16(3):197-200. [2]张洪涛,白彦灵,葛晓峰,等.非小细胞肺癌三维适形放疗靶区和肺剂量学研究[J].中华放射肿瘤学杂志,2005,14(2):100-104. [3]梁军,冯勤付,张可,等.肺癌三维适形放疗与常规放疗剂量学优势的比较[J].临床肿瘤学杂志,2006,11(11):814-821. [4]Liu HH,Wang X,Dong L,et a1.Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2004,58(4):1268－1279. [5]Murshed H,Liu HH,Liao Z,et al Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung[J]. Int J Radiat Oncol Biol Phys,2004,58(4):1258－1267. [6]朱正飞,傅小龙,徐志勇,等.调强放疗与三维适形放疗在非小细胞肺癌中的剂量学比较[J].中华放射肿瘤学杂志,2009,18(5):352-356. [7]Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy[J]. Int J Radiat Oncol Biol Phys,2007,68(1):94-102. [8]Christian JA, Bedford JL, Webb S, et al. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2007,67(3):735-741. [9]Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer:a comparison of intensity modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation[J]. Int J Radiat Oncol Biol Phys,2003,57(3):875-890. [10]Nakayama H, Satoh H, Kurishima K, et al. High-dose conformal radiotherapy for patients with stage Ⅲ non-small-cell lung carcinoma[J]. Int J Radiat Oncol Biol Phys,2010,78(3):645-650.DOI:10.1016/j.ijrobp.2009.08.037. [11]Sher DJ, Koshy M, Liptay MJ, et al. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage Ⅲ non-small cell lung cancer in the National Cancer Data Base[J]. Cancer,2014, 20(13):2060-2068. DOI:10.1002/cncr.28677. [12]Harris JP, Murphy JD, Hanlon AL, et al. A population-based comparative effectiveness study of radiation therapy techniques in stage Ⅲ non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2014,88(4):872-884. [13]曹建忠,欧广飞,梁军,等.三维适形放疗治疗局部晚期非小细胞肺癌的疗效[J].中华肿瘤杂志,2011,33(7):529-534.DOI:10.3760/cnm.j.issn.0253-3766.2011.07.013 [14]Liao ZX, Komaki RR, Thames HD Jr, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys,2010,76(3):775-781.DOI:10.1016/j.ijrobp.2009.02.032. [15]Feinstein F, Sosin D, Wells C. The Will Rogers phenomenon. Stage migration and new diagnostic technoniques as a source of misleading statitics for survival in cancer[J]. N Engl J Med,1985,312(25):1604-1608. [16]Wang JZ, Li XA, D′Souza WD, et al. Impact of prolonged fraction delivery times on tumor control:a note of caution for intensity-modulated radiation therapy (IMRT)[J]. Int J Radiat Oncol Biol Phys,2003,57(2):543-552. [17]Wang X, Xiong XP, Lu J, et al. The in vivo study on the radiobiologic effect of prolonged delivery time to tumor control in C57BL mice implanted with Lewis lung cancer[J/OL]. Radiat Oncol,2011,6:4[2014-06-10]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024935/.DOI:10.1186/1748－717X-6-4. [18]徐裕金,刘冠,王准,等.局部晚期非小细胞肺癌同步加量调强放疗的回顾性分析[J].中华放射医学与防护杂志,2013,33(2):146-150.DOI:0.3760/cma.j.issn.0254-5098.2013.02.009. [19]Ji K, Zhao LJ, Liu WS, et al. Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer:a retrospective clinical study[J]. Br J Radiol,2014,87(1035):20130562.DOI:10.1259/bjr.20130562.
2015, Vol. 24 
